Across TCGA pan-cancer cohorts, IQCJ RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated IQCJ data layer compared with 1 for mutation status.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IQCJ RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated IQCJ expression acts as an unfavorable survival marker, although some lineages such as LUAD and MESO show a favorable association.
STAD, OV, and UVM are the cancer types where IQCJ RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.